Literature DB >> 8758903

A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.

D B Berman1, J Costalas, D C Schultz, G Grana, M Daly, A K Godwin.   

Abstract

Recent studies have identified mutations in the breast and (ovarian cancer susceptibility gene 2 (BRCA2), one which has been found in the germline of several males and one female affected with breast cancer. To establish the carrier frequency of this mutation in a large population of individuals affected with cancer, we evaluated constitutional DNA isolated from 83 individuals diagnosed with breast cancer and 93 diagnosed with ovarian cancer at any age, 42 of whom reported a family history of cancer. Using a simple allele-specific PCR-based nonradioactive method, we detected a total of eight individuals (4.5%) carrying a 1-bp deletion at nucleotide 6174 of the BRCA2 gene (6174delT). The age of disease onset in the mutant allele carriers was highly variable and typically late onset (41-72 years for breast cancer and 48-73 years for ovarian cancer). Evaluation of family histories for the eight mutant allele carriers revealed that several individuals had significant cancer histories that included, in addition to breast and/or ovarian cancer, an increased incidence of colon, esophageal, pancreatic, stomach, and hematopoietic cancers. Interestingly, seven of the eight individuals were of Ashkenazi Jewish descent. Haplotype data for the mutant allele carriers using markers spanning the region of the BRCA2 gene on chromosome 13ql2-ql3 suggest that only two of the confirmed Jewish Ashkenazi individuals share a single common ancestry, indicating several independent origins for this mutation. These data provide evidence for the presence of a specific BRCA2 mutation which has its origins in both Jewish Ashkenazi and non-Jewish populations. The observed overrepresentation of specific mutations within a subgroup of the general population may eventually help contribute to the development of inexpensive and routine tests such as the one described in our study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758903

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Single nucleotide polymorphism seeking long term association with complex disease.

Authors:  Brian W Kirk; Matthew Feinsod; Reyna Favis; Richard M Kliman; Francis Barany
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

Review 2.  [Evaluation of cancer risk through genetic analysis?].

Authors:  A Luz
Journal:  Strahlenther Onkol       Date:  1997-09       Impact factor: 3.621

3.  BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.

Authors:  Bernard Friedenson
Journal:  MedGenMed       Date:  2005-06-29

4.  BRCA2 mutations in hereditary breast and ovarian cancer in France.

Authors:  O M Serova-Sinilnikova; L Boutrand; D Stoppa-Lyonnet; B Bressac-de-Paillerets; V Dubois; C Lasset; N Janin; Y J Bignon; M Longy; C Maugard; R Lidereau; D Leroux; T Frebourg; S Mazoyer; G M Lenoir
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

Review 5.  DNA repair dysregulation from cancer driver to therapeutic target.

Authors:  Nicola J Curtin
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

6.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 7.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

8.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Authors:  P N Tonin; A M Mes-Masson; P A Futreal; K Morgan; M Mahon; W D Foulkes; D E Cole; D Provencher; P Ghadirian; S A Narod
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

9.  Mitochondrial DNA mutations in pancreatic cancer.

Authors:  Keyanoosh Kassauei; Nils Habbe; Michael E Mullendore; Collins A Karikari; Anirban Maitra; Georg Feldmann
Journal:  Int J Gastrointest Cancer       Date:  2006

Review 10.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.